2-[1-[2-[(2,6-dichloro-4-pyridyl)amino]-2-oxoethyl]-5-methyl-2,4-dioxoquinazolin-3-yl]acetic acid | 1052723-17-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-[1-[2-[(2,6-dichloro-4-pyridyl)amino]-2-oxoethyl]-5-methyl-2,4-dioxoquinazolin-3-yl]acetic acid
• 英文别名: {1-[(2,6-dichloro-pyridin-4-ylcarbamoyl)-methyl]-5-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid；2-[1-[2-[(2,6-Dichloropyridin-4-yl)amino]-2-oxoethyl]-5-methyl-2,4-dioxoquinazolin-3-yl]acetic acid
• CAS: 1052723-17-7
• 化学式: C₁₈H₁₄Cl₂N₄O₅
• 分子量: 437.239
• InChiKey: SFLGIBXGHYNHHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-(5-chloro-2,4-dimethoxy-phenyl)-2-{3-[((S)-1-cyclohexylmethyl-2-hydroxyethylcarbamoyl)-methyl]-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl}-acetamide 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-[1-[2-[(2,6-dichloro-4-pyridyl)amino]-2-oxoethyl]-5-methyl-2,4-dioxoquinazolin-3-yl]acetic acid
  参考文献：
  名称：

  WO2008/107436

  摘要：

  公开号：

文献信息

• BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS
  申请人：Taylor Roger John

  公开号：US20100113774A1

  公开（公告）日：2010-05-06

  A compound of formula (I): in free or salt form, wherein A, R 1 , R 3 , Q a , Q b and Q are as defined herein, for the treatment of a disease mediated by the S1P2 or S1P3 receptor, such as inflammatory or obstructive airways disease.

  一种化合物，其分子式为（I）：以自由或盐形式存在，其中A，R1，R3，Qa，Qb和Q的定义如下，用于治疗由S1P2或S1P3受体介导的疾病，例如炎症性或阻塞性气道疾病。
• Treatment of familial exudative vitreoretinopathy through S1PR2 inhibition
  申请人：DALHOUSIE UNIVERSITY

  公开号：US10058543B2

  公开（公告）日：2018-08-28

  Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.

  本研究提供了通过施用治疗有效量的2型磷酸肾上腺素受体（S1PR2）抑制剂来治疗家族性渗出性玻璃体视网膜病变（FEVR）和早产儿视网膜病变（ROP）的方法和组合物。
• S1PR2 antagonists and uses therefor
  申请人：DALHOUSIE UNIVERSITY

  公开号：US10858358B2

  公开（公告）日：2020-12-08

  Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are (Z)-2-cyano-1-(2,6-dichloropyridin-4-yl)-3-((4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)methyl)guanidine and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.

  提供了通过施用治疗有效量的鞘氨醇-1-磷酸受体 2 型（S1PR2）拮抗剂治疗家族性渗出性玻璃体视网膜病变（FEVR）的方法和组合物。本文还提供了(Z)-2-氰基-1-(2,6-二氯吡啶-4-基)-3-((4-异丙基-1,3-二甲基-1H-吡唑并[3,4-b]吡啶-6-基)甲基)胍及其类似物，以及它们在治疗视网膜病变和以血管生成不足为特征的疾病中的用途。
• TREATMENT OF FAMILIAL EXUDATIVE VITREORETINOPATHY THROUGH S1PR2 INHIBITION
  申请人：DALHOUSIE UNIVERSITY

  公开号：US20170135997A1

  公开（公告）日：2017-05-18

  Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.
• S1PR2 ANTAGONISTS AND USES THEREFOR
  申请人：Dalhousie University

  公开号：US20180141942A1

  公开（公告）日：2018-05-24

  Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are compounds which contain bioisosteric replacements of the urea group of JTE-013 and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.